Biosimilars
Features
- All
- Analytical Services
- Bioanalytical Services
- Bioassay Development
- Biologics, Proteins, Vaccines
- Biosimilars
- Chemistry
- Clinical Trials
- Drug Delivery
- Drug Development
- Drug Discovery
- Formulation Development
- Information Technology
- Laboratory Testing
- Methods Development
- Microbiology
- Preclinical Outsourcing
- R&D
- Toxicology
-
Biosimilars | Breaking News
Sandoz’s Wyost and Jubbonti Granted EC Marketing Authorization
Become the first and only biosimilar versions of Amgen's medicines Xgeva and Prolia in Europe.05.22.24
-
Biosimilars | Breaking News | Collaborations & Alliances
Boehringer Ingelheim Inks Deal to Expand Patient Access to adalimumab-adbm Injection
Will manufacture its Humira biosimilar for Quallent.05.13.24
-
Biosimilars | Breaking News | Promotions & Moves
MAbxience Names New Chief Executive Officer
Jurgen Van Broeck brings experience and a proven track record in the pharmaceutical and biosimilar industries.05.10.24
-
Biologics, Proteins, Vaccines | Biosimilars
Real-Time Kinetic Data in the Successful Dev of an Inhibition of Proliferation Potency Bioassay
The quantitative measurement of potency plays a critical role in biopharmaceutical development.04.10.24
-
Biosimilars | Regulatory Affairs
Inflation Reduction Act and the Impact on Biosimilars
Exploring the IRA’s provisions and their impact to biosimilars.Dinakaran (Dina) Balasubramanian, Dr. Reddy's Laboratories 04.10.24
-
Biologics, Proteins, Vaccines | Biosimilars
Underlying Economics of Unbranded Biologics
Unbranded biologics exist is to protect the gross list price of the branded variant.Online Exclusives Dinakaran Balasubramanian, Dr. Reddy’s Laboratories 04.05.24
-
Biosimilars
Inflation Reduction Act and the Impact on Biosimilars
Exploring the IRA’s provisions and their impact to biosimilars.Online Exclusives Dinakaran Balasubramanian, Dr. Reddy’s Laboratories 03.15.24
-
Biosimilars | Regulatory Affairs
Regulatory Affairs: The Generic Industry Faces External Challenges
Insights from the regulatory experts at Lachman Consultants.Bob Pollock, Senior Advisor, Outside Director to the Board, Lachman Consultant Services, Inc. 03.04.24
-
Biosimilars | Breaking News | cGMP Manufacture | Solid Dosage/Creams/Ointments
JAMP Pharma Group Acquires Manufacturing Facility in Quebec
Strengthens the Canadian supply chain and contributes to addressing drug shortages.03.01.24
-
Bio News | Biosimilars | Breaking News
Fresenius Kabi Introduces Cyclophosphamide for Injection, USP
Serves as a generic substitute for Cytoxan, for use in treating several forms of cancer.02.28.24
-
Biosimilars | Breaking News | Collaborations & Alliances
FDA Approves First Interchangeable High-Concentration, Citrate-Free Biosimilar to Humira
Teva is Alvotech’s strategic partner for the exclusive commercialization of SIMLANDI in the United States.02.26.24
-
Biosimilars | Breaking News | cGMP Manufacture
Chanelle Pharma Founder Sells Company to Private Equity Firm
Chanelle will remain an Irish managed company with the current management team remaining in place.02.13.24
-
Biosimilars | Breaking News | Industry News
Sandoz to Acquire U.S. Biosimilar CIMERLI
Inclusive of biologics license application, product inventory, ophthalmology sales and field reimbursement talent.01.24.24
-
Biosimilars | Breaking News | cGMP Manufacture | Collaborations & Alliances | Drug Development
Chime Biologics, Kings Pharm Partner to Accelerate Biosimilar Launch
Chime will provide cell line development, process development, global GMP manufacturing, commercialization, and regulatory filing support.09.25.23
-
Biosimilars | Breaking News | cGMP Manufacture | Collaborations & Alliances | Drug Development
Teva Pharmaceuticals, Alvotech Expand Strategic Biosimilars Pact
Teva gains exclusive commercialization of two new biosimilar candidates in the U.S. and line extensions of two current biosimilar candidates.07.25.23
-
Biosimilars | Breaking News | cGMP Manufacture | Industry News
Samsung Biologics, Pfizer Partner to Manufacture Biosimilars Portfolio
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio.06.08.23
-
Biosimilars | Breaking News | cGMP Manufacture | Drug Development | Industry News
Evotec Biologics, Sandoz Enter Biosimilars Development & Mfg. Pact
Partnership supports Sandoz pipeline expansion to 24 biosimilar assets.05.11.23
-
Biosimilars
-
Bio News | Biosimilars | Breaking News | Collaborations & Alliances | Drug Development | Industry News
Similis Bio Partners With Novel351k to Develop Multiple Biosimilar Programs
Novel351k will leverage its experience with regulatory and clinical strategies to accelerate the development of the programs toward commercialization.02.15.23
-
Biosimilars | Breaking News | Industry News
Biocon Completes Acquisition of Viatris' Global Biosimilars Business
Creates an integrated, leading global biosimilars enterprise with eight commercialized products.Videos11.29.22
